Evidence map›Paper›PMID 26292633›Full record

ArticleClinical rheumatology2015

Occurrence of Sweet syndrome under anti-TNF.

Christopher Banse, Valérie Sobocinski, Guillaume Savoye, Gilles Avenel, Olivier Vittecoq

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher BanseDepartment of Rheumatology, CHU de Rouen, Hôpitaux de Rouen, Inserm U905, University of Rouen, 147 avenue du Maréchal Juin, 76230, Bois-Guillaume, Rouen, France. totobanse@orange.fr.
Valérie SobocinskiDepartment of Dermatology and Pharmacovigilance, CHU de Rouen, Hôpitaux de Rouen, University of Rouen, Rouen, France.
Guillaume SavoyeDepartment of Hepato-Gastro-Enterology, CHU de Rouen, Hôpitaux de Rouen, University of Rouen, Rouen, France.
Gilles AvenelDepartment of Rheumatology, CHU de Rouen, Hôpitaux de Rouen, Inserm U905, University of Rouen, 147 avenue du Maréchal Juin, 76230, Bois-Guillaume, Rouen, France.
Olivier VittecoqDepartment of Rheumatology, CHU de Rouen, Hôpitaux de Rouen, Inserm U905, University of Rouen, 147 avenue du Maréchal Juin, 76230, Bois-Guillaume, Rouen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the occurrence of Sweet's syndrome in a patient treated with adalimumab for Crohn's disease. The imputability of adalimumab is at issue.

Indexed as

AdalimumabAdultCorticosteroneCrohn DiseaseFemaleHumansRecurrenceSweet SyndromeTumor Necrosis Factor-alphaAdalimumabCorticosteroneTumor Necrosis Factor-alphaAdalimumabBiotherapyNeutrophilic dermatosisSweet syndrome

Identifiers

PMID26292633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.